| Literature DB >> 26667790 |
Peter M Kreuzer1,2, Astrid Lehner1,2, Winfried Schlee1,2, Veronika Vielsmeier3,2, Martin Schecklmann1,2, Timm B Poeppl1,2, Michael Landgrebe1,4,2, Rainer Rupprecht1, Berthold Langguth1,2.
Abstract
Repetitive transcranial magnetic stimulation (rTMS) has been proposed as a tinnitus treatment option. Promising results have been obtained by consecutive stimulation of lateral frontal and auditory brain regions. We investigated a combined stimulation paradigm targeting the anterior cingulate cortex (ACC) with double cone coil rTMS, followed by stimulation of the temporo-parietal junction area with a figure-of-eight coil. The study was conducted as a randomized, double-blind pilot trial in 40 patients suffering from chronic tinnitus. We compared mediofrontal stimulation with double-cone-coil, (2000 stimuli, 10 Hz) followed by left temporo-parietal stimulation with figure-of-eight-coil (2000 stimuli, 1 Hz) to left dorsolateral-prefrontal-cortex stimulation with figure-of-eight-coil (2000 stimuli, 10 Hz) followed by temporo-parietal stimulation with figure-of-eight-coil (2000 stimuli, 1 Hz). The stimulation was feasible with comparable dropout rates in both study arms; no severe adverse events were registered. Responder rates did not differ in both study arms. There was a significant main effect of time for the change in the TQ score, but no significant time x group interaction. This pilot study demonstrated the feasibility of combined mediofrontal/temporoparietal-rTMS-stimulation with double cone coil in tinnitus patients but failed to show better outcome compared to an actively rTMS treated control group.Entities:
Mesh:
Year: 2015 PMID: 26667790 PMCID: PMC4678896 DOI: 10.1038/srep18028
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Structure of the present “TiCDC” pilot trial; (for detailed information see methods’ section).
Baseline characteristics of patients.
| TiCDC( | Standard rTMS( | Statistics | |
|---|---|---|---|
| gender (female/male) | 5/13 | 6/12 | χ2(1) = 0.131, |
| age (years) | 50.9 ± 10.7 | 54.4 ± 9.0 | |
| tinnitus duration in months | 78.3 ± 79.7 | 97.0 ± 143.8 | |
| tinnitus laterality (right/left/both) | 1/2/15 | 2/5/11 | χ2(5) = 3.562, |
| TQ total score | 32.3 ± 19.3 | 33.8 ± 17.7 | |
| THI total score | 38.3 ± 21.8 | 36.6 ± 21.8 | |
| MDI | 7.1 ± 5.8 | 6.9 ± 6.3 |
TQ: Tinnitus Questionnaire, THI: Tinnitus Handicap Inventory, MDI: Major Depression Inventory.
Figure 2TiCDC study patient flow.
Responder Analysis.
| Week 2 visit (end of treatment)- primary outcome - | responder | non-responder |
|---|---|---|
| both groups | 11 | 25 |
| TiCDC | 6 | 12 |
| standard rTMS | 5 | 13 |
| statistics | χ2(1) = 0.131, | |
| Week 12 visit (end of study) | ||
| both groups | 14 | 22 |
| TiCDC | 9 | 9 |
| standard rTMS | 5 | 13 |
| statistics | χ2(1) = 1.870; | |
Secondary outcomes: ANOVA with between subjects factor group (‘TiCDC’ vs. ‘standard rTMS’) and within subjects factor time (baseline vs. week 12).
| main effect time | interaction effects for group x time (baseline vs. week 12) | |||||
|---|---|---|---|---|---|---|
| part. Eta2 | part. Eta2 | |||||
| TQ | 5.085 | 0.031 | 0.130 | 1.431 | 0.240 | 0.040 |
| THI | 3.459 | 0.072 | 0.092 | 3.459 | 0.072 | 0.092 |
| TBF12 | 0.150 | 0.701 | 0.004 | 2.265 | 0.142 | 0.062 |
| MDI | 2.222 | 0.145 | 0.061 | 1.502 | 0.229 | 0.042 |
| WHOQOL1 | 1.956 | 0.171 | 0.054 | 3.412 | 0.073 | 0.091 |
| WHOQOL2 | 0.176 | 0.678 | 0.005 | 1.477 | 0.233 | 0.042 |
| WHOQOL3 | 0.103 | 0.751 | 0.003 | 1.499 | 0.229 | 0.042 |
| WHOQOL4 | 0.067 | 0.789 | 0.002 | 1.351 | 0.253 | 0.038 |
TQ: Tinnitus Questionnaire, THI: Tinnitus Handicap Inventory, MDI: Major Depression Inventory, WHOQoL: World Health Organization Quality of Life Questionnaire (Domain 1–4), TBF12: Tinnitus Impairment Questionnaire (short version of the THI consisting of 12 items).
Clinical Global Impression (CGI) at week 2 and week 12.
| Week 2 visit(end of treatment) | much better | minimallybetter | no change | minimallyworse |
|---|---|---|---|---|
| both groups | 3 | 8 | 16 | 6 |
| TiCDC | 2 | 4 | 7 | 3 |
| standard rTMS | 1 | 4 | 9 | 3 |
| statistics | χ2(3, | |||
| Week 12 visit (end of study) | ||||
| both groups | 3 | 5 | 17 | 4 |
| TiCDC | 1 | 2 | 9 | 2 |
| standard rTMS | 2 | 3 | 8 | 2 |
| statistics | χ2(3, | |||
Figure 3Tinnitus Questionnaire Scores (mean/sem).
rTMS treatment took place between baseline and week 2 visit. Week 4 and 12 visits represent follow up.